| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.PHARMTHERA.2017.02.010 |
| P8608 | Fatcat ID | release_qeatk3wwbvazrpx3rnzqzafsci |
| P932 | PMC publication ID | 5777523 |
| P698 | PubMed publication ID | 28174094 |
| P2093 | author name string | Ram I Mahato | |
| Rinku Dutta | |||
| P2860 | cites work | MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib | Q24655048 |
| Diagnostics and Treatment of Hepatocellular Carcinoma in 2016: Standards and Developments | Q26740315 | ||
| New advances in hepatocellular carcinoma | Q26749329 | ||
| Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region | Q26750444 | ||
| Recent Advances in Antiviral Therapy for Chronic Hepatitis C | Q26750476 | ||
| Hepatocellular carcinoma: Where are we? | Q26765182 | ||
| MicroRNAs as Biomarkers for Liver Disease and Hepatocellular Carcinoma | Q26765476 | ||
| Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma | Q26772321 | ||
| Systemic therapies for hepatocellular carcinoma | Q26775193 | ||
| Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma | Q26823523 | ||
| miR-122 is a unique molecule with great potential in diagnosis, prognosis of liver disease, and therapy both as miRNA mimic and antimir | Q26991956 | ||
| Human occludin is a hepatitis C virus entry factor required for infection of mouse cells | Q27490169 | ||
| Management of hepatocellular carcinoma: An update | Q27860530 | ||
| Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities | Q42024872 | ||
| ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development | Q42199386 | ||
| Therapeutic potential of small interfering RNAs/micro interfering RNA in hepatocellular carcinoma | Q42434482 | ||
| A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. | Q42989841 | ||
| Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies | Q43041465 | ||
| Targeting hepatic cancer cells with pegylated dendrimers displaying N-acetylgalactosamine and SP94 peptide ligands | Q43845180 | ||
| [Clinical value of iodine [131I] metuximab infusion combined with TACE for treatment of patients with post-intervention relapse of mid or advanced stage hepatocellular carcinoma]. | Q44267804 | ||
| A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma | Q44930012 | ||
| Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. | Q45980006 | ||
| SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. | Q50454368 | ||
| Phase I trial of multidrug resistance-associated protein 3-derived peptide in patients with hepatocellular carcinoma. | Q50712098 | ||
| Carboxymethyl Dextran-Stabilized Polyethylenimine-Poly(epsilon-caprolactone) Nanoparticles-Mediated Modulation of MicroRNA-34a Expression via Small-Molecule Modulator for Hepatocellular Carcinoma Therapy. | Q50798066 | ||
| iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy. | Q50870799 | ||
| mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib. | Q51452386 | ||
| Metronomic S-1 chemotherapy plus transcatheter arterial chemoembolization (TACE): a promising treatment of hepatocellular carcinoma refractory to TACE. | Q51789583 | ||
| Tumor pH(e)-triggered charge-reversal and redox-responsive nanoparticles for docetaxel delivery in hepatocellular carcinoma treatment. | Q52918204 | ||
| Low miR-29c expression is a prognostic marker in hepatocellular carcinoma. | Q53036075 | ||
| Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. | Q53162619 | ||
| Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice | Q81208649 | ||
| Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma | Q84546774 | ||
| Hepatocellular carcinoma | Q85238211 | ||
| Liposomes for targeting hepatocellular carcinoma: use of conjugated arabinogalactan as targeting ligand | Q85774171 | ||
| Multilayer-Coated Liquid Crystalline Nanoparticles for Effective Sorafenib Delivery to Hepatocellular Carcinoma | Q86021332 | ||
| Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma | Q28118779 | ||
| Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry | Q28131832 | ||
| Aptamer-functionalized peptide H3CR5C as a novel nanovehicle for codelivery of fasudil and miRNA-195 targeting hepatocellular carcinoma | Q28829736 | ||
| Claudin association with CD81 defines hepatitis C virus entry. | Q29465808 | ||
| Hepatocellular carcinoma pathogenesis: from genes to environment | Q29615767 | ||
| Hepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals. | Q30386551 | ||
| Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial | Q33410643 | ||
| Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial | Q33423800 | ||
| 131I-Labeled-Metuximab Plus Transarterial Chemoembolization in Combination Therapy for Unresectable Hepatocellular Carcinoma: Results from a Multicenter Phase IV Clinical Study | Q33428038 | ||
| Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma. | Q33433311 | ||
| PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells | Q33847621 | ||
| Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies | Q33895113 | ||
| Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor | Q34245963 | ||
| In vivo activity of nuclease-resistant siRNAs | Q34365687 | ||
| Elimination pathways of systemically delivered siRNA. | Q34556940 | ||
| Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial | Q34663499 | ||
| Mammalian ABC transporters in health and disease | Q34667449 | ||
| Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial | Q34786090 | ||
| Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma | Q35051445 | ||
| Chemopreventive strategies in hepatocellular carcinoma | Q35101365 | ||
| Immunotherapy for hepatocellular carcinoma: From basic research to clinical use. | Q35567765 | ||
| The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. | Q35779648 | ||
| Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, Identify Cirrhotic Patients with HCC. | Q35824254 | ||
| Targeted delivery of chemically modified anti-miR-221 to hepatocellular carcinoma with negatively charged liposomes | Q35914942 | ||
| Novel Glypican-3-Binding Peptide for in Vivo Hepatocellular Carcinoma Fluorescent Imaging | Q35916218 | ||
| Anticancer drugs cause release of exosomes with heat shock proteins from human hepatocellular carcinoma cells that elicit effective natural killer cell antitumor responses in vitro | Q35939788 | ||
| Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma | Q35965943 | ||
| Hepatocellular carcinoma: molecular pathways and new therapeutic targets. | Q36140308 | ||
| Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients | Q36204431 | ||
| Serum exosomal microRNAs as novel biomarkers for hepatocellular carcinoma | Q36294432 | ||
| Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma | Q36334145 | ||
| Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease | Q36402141 | ||
| Folate receptor-targeted liposomes loaded with a diacid metabolite of norcantharidin enhance antitumor potency for H22 hepatocellular carcinoma both in vitro and in vivo | Q36798011 | ||
| Peptide vaccines for hepatocellular carcinoma | Q36888010 | ||
| Relation between microRNAs and Apoptosis in Hepatocellular Carcinoma | Q36945012 | ||
| Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium. | Q38824017 | ||
| Visualization of hepatitis B virus entry - novel tools and approaches to directly follow virus entry into hepatocytes | Q38826563 | ||
| Advanced Hepatocellular Cancer: the Current State of Future Research | Q38848537 | ||
| Glycyrrhetinic Acid-Mediated Polymeric Drug Delivery Targeting the Acidic Microenvironment of Hepatocellular Carcinoma | Q38856193 | ||
| The promotion of salinomycin delivery to hepatocellular carcinoma cells through EGFR and CD133 aptamers conjugation by PLGA nanoparticles | Q38857110 | ||
| Cell death-inducing DFFA-like effector b is required for hepatitis C virus entry into hepatocytes | Q38994889 | ||
| Overexpression of GPC3 inhibits hepatocellular carcinoma cell proliferation and invasion through induction of apoptosis | Q39206940 | ||
| MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma | Q39414132 | ||
| iRGD-Decorated Polymeric Nanoparticles for the Efficient Delivery of Vandetanib to Hepatocellular Carcinoma: Preparation and in Vitro and in Vivo Evaluation | Q39629173 | ||
| Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery | Q40001445 | ||
| Downregulation of microRNA-122 promotes proliferation, migration, and invasion of human hepatocellular carcinoma cells by activating epithelial-mesenchymal transition | Q40039824 | ||
| Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma | Q40283613 | ||
| RGD peptide targeted lipid coated nanoparticles for combinatorial delivery of sorafenib and quercetin against hepatocellular carcinoma | Q40688909 | ||
| Effect of integrin receptor-targeted liposomal paclitaxel for hepatocellular carcinoma targeting and therapy | Q41110002 | ||
| Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. | Q41482573 | ||
| Identification of transferrin receptor 1 as a hepatitis C virus entry factor | Q36967731 | ||
| Novel approaches to treatment of hepatocellular carcinoma and hepatic metastases using thermal ablation and thermosensitive liposomes. | Q37083651 | ||
| Investigation of SP94 Peptide as a Specific Probe for Hepatocellular Carcinoma Imaging and Therapy | Q37271850 | ||
| Evolving therapies in the treatment of hepatocellular carcinoma | Q37290714 | ||
| Fate of fat: the role of adipose triglyceride lipase in lipolysis | Q37326006 | ||
| Multimodal approaches to the treatment of hepatocellular carcinoma | Q37384682 | ||
| Targeted therapy for hepatocellular carcinoma | Q37504684 | ||
| Circulating microRNA profiles in plasma: identification of miR-224 as a novel diagnostic biomarker in hepatocellular carcinoma independent of hepatic function | Q37619833 | ||
| Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application | Q37665303 | ||
| A fresh look at NASH pathogenesis. Part 1: the metabolic movers. | Q37759155 | ||
| Sterile inflammation in the liver | Q38043897 | ||
| Genetic susceptibility to type 2 diabetes and obesity: from genome-wide association studies to rare variants and beyond | Q38214522 | ||
| Physiological roles of asialoglycoprotein receptors (ASGPRs) variants and recent advances in hepatic-targeted delivery of therapeutic molecules via ASGPRs | Q38224292 | ||
| Macrophages, immunity, and metabolic disease | Q38230879 | ||
| Hepatocellular carcinoma and microRNA: new perspectives on therapeutics and diagnostics | Q38275679 | ||
| Significant biomarkers for the management of hepatocellular carcinoma | Q38412315 | ||
| Tivantinib (ARQ197) in hepatocellular carcinoma | Q38513062 | ||
| Novel drugs in clinical development for hepatocellular carcinoma | Q38537138 | ||
| Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo | Q38541397 | ||
| Oncogenic signaling pathways and origins of tumor-initiating stem-like cells of hepatocellular carcinomas induced by hepatitis C virus, alcohol and/or obesity. | Q38552480 | ||
| Immunological landscape and immunotherapy of hepatocellular carcinoma | Q38611895 | ||
| Status of and prospects for cancer vaccines against hepatocellular carcinoma in clinical trials | Q38621919 | ||
| Progress in the development of vaccines for hepatitis C virus infection | Q38635596 | ||
| Glycyrrhetinic Acid Mediated Drug Delivery Carriers for Hepatocellular Carcinoma Therapy. | Q38710684 | ||
| A Review and Update of Treatment Options and Controversies in the Management of Hepatocellular Carcinoma | Q38712688 | ||
| Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD. | Q38752448 | ||
| Circulating microRNAs in Hepatocellular Carcinoma: Potential Diagnostic and Prognostic Biomarkers | Q38758317 | ||
| Design of cholesterol arabinogalactan anchored liposomes for asialoglycoprotein receptor mediated targeting to hepatocellular carcinoma: In silico modeling, in vitro and in vivo evaluation | Q38768210 | ||
| Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin | Q38788994 | ||
| Mechanisms of HBV-induced hepatocellular carcinoma. | Q38809557 | ||
| Vaccination with liposome-coupled glypican-3-derived epitope peptide stimulates cytotoxic T lymphocytes and inhibits GPC3-expressing tumor growth in mice | Q38816046 | ||
| Doxorubicin-transferrin conjugate triggers pro-oxidative disorders in solid tumor cells. | Q38816743 | ||
| Targeted Therapy for Hepatocellular Carcinoma | Q38822106 | ||
| Pathogenesis of alcoholic liver disease | Q38823745 | ||
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| P304 | page(s) | 106-117 | |
| P577 | publication date | 2017-02-04 | |
| P1433 | published in | Pharmacology & Therapeutics | Q3378596 |
| P1476 | title | Recent advances in hepatocellular carcinoma therapy | |
| P478 | volume | 173 |
| Q90336645 | 18-GA-Suc Modified Liposome Loading Cantharidin for Augmenting Hepatic Specificity: Preparation, Characterization, Antitumor Effects, and Liver-Targeting Efficiency |
| Q47156979 | A comprehensive genome-wide analysis of long noncoding RNA expression profile in hepatocellular carcinoma |
| Q92932054 | Anticancer activity of dietary xanthone α-mangostin against hepatocellular carcinoma by inhibition of STAT3 signaling via stabilization of SHP1 |
| Q90289906 | Arctigenin Attenuates Tumor Metastasis Through Inhibiting Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma via Suppressing GSK3β-Dependent Wnt/β-Catenin Signaling Pathway In Vivo and In Vitro |
| Q64996715 | Axis inhibition protein 1 (Axin1) Deletion-Induced Hepatocarcinogenesis Requires Intact β-Catenin but Not Notch Cascade in Mice. |
| Q100945779 | BCL11B suppresses tumor progression and stem cell traits in hepatocellular carcinoma by restoring p53 signaling activity |
| Q47144046 | Bifunctional enzyme ATIC promotes propagation of hepatocellular carcinoma by regulating AMPK-mTOR-S6 K1 signaling. |
| Q90409382 | Bisdemethoxycurcumin Inhibits Hepatocellular Carcinoma Proliferation Through Akt Inactivation via CYLD-Mediated Deubiquitination |
| Q92376888 | CBX3/HP1γ promotes tumor proliferation and predicts poor survival in hepatocellular carcinoma |
| Q64055633 | CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110β and predicts poor prognosis |
| Q58795154 | CEP55 Promotes Cell Motility via JAK2⁻STAT3⁻MMPs Cascade in Hepatocellular Carcinoma |
| Q89910216 | Cancer nanotechnology: Enhancing tumor cell response to chemotherapy for hepatocellular carcinoma therapy |
| Q99629822 | Circular RNA circ_0000517 regulates hepatocellular carcinoma development via miR-326/IGF1R axis |
| Q92669123 | Clinicopathological significance of TM4SF5 expression in human hepatocellular carcinoma tissues |
| Q89791281 | Combining transcatheter arterial embolization with iodized oil containing Apatinib inhibits HCC growth and metastasis |
| Q90370682 | Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib |
| Q60306455 | Curcumin-loaded galactosylated BSA nanoparticles as targeted drug delivery carriers inhibit hepatocellular carcinoma cell proliferation and migration |
| Q92048062 | Development of Asialoglycoprotein Receptor-Targeted Nanoparticles for Selective Delivery of Gemcitabine to Hepatocellular Carcinoma |
| Q90675200 | Dual-Responsive Core Crosslinking Glycopolymer-Drug Conjugates Nanoparticles for Precise Hepatocarcinoma Therapy |
| Q92557168 | Establishment of an insufficient radiofrequency ablation orthotopic nude mouse model of hepatocellular carcinoma to study the invasiveness and metastatic potential of residual cancer |
| Q90279945 | Exosomal MiR-744 Inhibits Proliferation and Sorafenib Chemoresistance in Hepatocellular Carcinoma by Targeting PAX2 |
| Q47140323 | Fibrinogen and C-reactive protein score is a prognostic index for patients with hepatocellular carcinoma undergoing curative resection: a prognostic nomogram study |
| Q61818499 | GAS5 Regulates RECK Expression and Inhibits Invasion Potential of HCC Cells by Sponging miR-135b |
| Q89127919 | Hyaluronic acid/doxorubicin nanoassembly-releasing microspheres for the transarterial chemoembolization of a liver tumor |
| Q57490701 | Identification of WDR12 as a novel oncogene involved in hepatocellular carcinoma propagation |
| Q47127018 | Identifying key regulating miRNAs in hepatocellular carcinomas by an omics' method |
| Q64914155 | Identifying miRNA-mRNA Pairs and Novel miRNAs from Hepatocelluar Carcinoma miRNomes and TCGA Database. |
| Q90136108 | Impact of national Human Development Index on liver cancer outcomes: Transition from 2008 to 2018 |
| Q98224253 | Interleukin 22 in Liver Injury, Inflammation and Cancer |
| Q92617793 | Knockdown of miR-106a suppresses migration and invasion and enhances radiosensitivity of hepatocellular carcinoma cells by upregulating FBXW7 |
| Q64064496 | Lactosylated Albumin Nanoparticles: Potential Drug Nanovehicles with Selective Targeting Toward an In Vitro Model of Hepatocellular Carcinoma |
| Q92327875 | Liver Cancer: Current and Future Trends Using Biomaterials |
| Q91892939 | Long Noncoding RNA RP5-833A20.1 Suppresses Tumorigenesis In Hepatocellular Carcinoma Through Akt/ERK Pathway By Targeting miR-18a-5p |
| Q92273727 | Long non-coding RNA F11-AS1 inhibits HBV-related hepatocellular carcinoma progression by regulating NR1I3 via binding to microRNA-211-5p |
| Q90115366 | Melatonin Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib through the PERK-ATF4-Beclin1 Pathway |
| Q93182677 | Myricetin Suppresses the Propagation of Hepatocellular Carcinoma via Down-Regulating Expression of YAP |
| Q47404057 | Natural Cyclopeptide RA-XII, a New Autophagy Inhibitor, Suppresses Protective Autophagy for Enhancing Apoptosis through AMPK/mTOR/P70S6K Pathways in HepG2 Cells. |
| Q97418362 | Network of clinically-relevant lncRNAs-mRNAs associated with prognosis of hepatocellular carcinoma patients |
| Q91564327 | Nucleostemin promotes hepatocellular carcinoma by regulating the function of STAT3 |
| Q89531796 | Oncogene-dependent function of BRG1 in hepatocarcinogenesis |
| Q90285730 | Overexpression of miRNA-21 Promotes the Proliferation and Invasion in Hepatocellular Carcinoma Cells via Suppressing SMAD7 |
| Q99608961 | Potential biomarkers Ang II/AT1R and S1P/S1PR1 predict the prognosis of hepatocellular carcinoma |
| Q60920865 | Radiation-Induced Reactions in The Liver - Modulation of Radiation Effects by Lifestyle-Related Factors |
| Q92156901 | Reversal of sorafenib resistance in hepatocellular carcinoma: epigenetically regulated disruption of 14-3-3η/hypoxia-inducible factor-1α |
| Q55516436 | Sinomenine hydrochloride inhibits cell survival in human hepatoma Huh7 cells. |
| Q90746674 | Systematic Investigation of Scutellariae Barbatae Herba for Treating Hepatocellular Carcinoma Based on Network Pharmacology |
| Q90411487 | The Dual Role of the Liver in Nanomedicine as an Actor in the Elimination of Nanostructures or a Therapeutic Target |
| Q100645482 | The Hsa_circ_0091579/miR-940/TACR1 Axis Regulates the Development of Hepatocellular Carcinoma |
| Q95262504 | The efficacy and safety of controlled low central venous pressure for liver resection: a systematic review and meta-analysis |
| Q54940514 | The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma. |
| Q64085684 | Traditional Chinese medicine formulation Yanggan Jiedu Sanjie inhibits TGF-β1-induced epithelial-mesenchymal transition and metastatic potential in human hepatocarcinoma Bel-7402 cells |
| Q49735252 | Uncovering the anticancer mechanism of Compound Kushen Injection against HCC by integrating quantitative analysis, network analysis and experimental validation |
Search more.